ArticleCureus2026
Albumin-Corrected Serum Calcium as a Biochemical Correlate of Left Ventricular Dysfunction Among Patients With End-Stage Renal Disease on Maintenance Hemodialysis: A Cross-Sectional Study.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCardiovascular disease is the leading cause of mortality in end-stage renal disease (ESRD), with left ventricular dysfunction (LVD) as its most consequential manifestation. Despite the well-established role of disturbed mineral metabolism in uremic cardiomyopathy, the calcium-phosphate (Ca×PO₄) product is widely used as a composite risk marker in ESRD management. This study aimed to determine the prevalence of LVD in ESRD patients on maintenance hemodialysis and to evaluate albumin-corrected calcium, Ca×PO₄ product, serum albumin, hemoglobin, and uric acid as cross-sectional correlates of left ventricular ejection fraction (LVEF). Sixty consecutive ESRD patients on stable thrice-weekly hemodialysis underwent predialysis transthoracic echocardiography, and LVD was defined as LVEF <50%. Total serum calcium was corrected for albumin using the Payne formula.
resultsLVD was present in 58.3% of patients (35/60); 35.0% met criteria for heart failure with reduced ejection fraction (LVEF <40%) and 23.3% for heart failure with mildly reduced ejection fraction (40%-49%). Among all biochemical parameters evaluated, albumin-corrected calcium was the sole independent associate of LVD on multivariate analysis (adjusted OR, 5.83; 95% CI, 1.84-18.42; p = 0.003), although causal inference is precluded by the cross-sectional design. Serum albumin demonstrated the strongest univariate biochemical correlation with LVEF (Spearman r = 0.701, p <0.001), exceeding corrected calcium (r = -0.488, p <0.001). The Ca×PO₄ product, in both uncorrected (r = -0.121, p = 0.358) and corrected form (r = -0.129, p = 0.329), did not predict LVD. Hemoglobin and uric acid similarly showed no significant association with LVEF. E/e' ratio was the strongest echocardiographic correlate of LVEF (r = -0.566, p <0.001) and was significantly elevated in the LVD group (median 13.9 vs. 10.8; p = 0.001).
conclusionsLVD is highly prevalent in ESRD patients on maintenance hemodialysis. Ca×PO₄ product does not show significant cross-sectional association with left ventricular systolic dysfunction in either corrected or uncorrected form. Albumin-corrected calcium was a key independent biochemical correlate of LVD in this cohort, while serum albumin emerged as an additional strong cardiac risk correlate warranting prospective evaluation. However, longitudinal studies are needed to determine whether these associations are causal and to inform clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.